For the development of new anti-obesity drugs, especially pancreatic lipase inhibitors, further studies on structure–activity relationships are required to establish new pharmacological leads based on the algal products. The gene discussed is PNLIP; the disease is obesity due to melanocortin 4 receptor deficiency.